Skip to content

Analysis of the Quality of Life, the Clinical Effectiveness and Cost-effectiveness of a Novel Educational Programme in Patients With Psoriasis and Atopic Dermatitis

Analysis of the Quality of Life, the Clinical Effectiveness and Cost-effectiveness of a Novel Educational Programme in Patients With Psoriasis and Atopic Dermatitis

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01077882
Acronym
OnderHUIDs
Enrollment
50
Registered
2010-03-01
Start date
2010-01-31
Completion date
2012-04-30
Last updated
2012-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis, Psoriasis

Keywords

Moderate and severe psoriasis and atopic dermatitis

Brief summary

'OnderHUIDs' is an educational program (Department of Dermatology, University Hospital, Gent) for patients with psoriasis and atopic dermatitis. We want to stimulate the patient to actively participate in their therapeutic approach by enhanced self care. We call the hypothesis that this program will help the patients learn to cope with their disease and to be loyal to their treatment, which will result in a better quality of life, better clinical outcome and cost effectiveness.

Interventions

BEHAVIORALeducation on skin disease conditions

information about several skin diseases skin function recommendation on care of skin

BEHAVIORALStress-reduction techniques

Physical Training yoga mindfulness-based stress reduction

BEHAVIORALLifestyle factors and psycho-education

by dietician and psychiatrist

standard care without educational program

Sponsors

University Hospital, Ghent
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Patients who have given written informed consent * Women or men of any race * Patients who are 18-75 years of age * Diagnosis of psoriasis or atopic dermatitis

Exclusion criteria

* Patients with a cognitive disorder (not able to understand, speak, read or write..) * Patients with a significant underlying medical cause (i.e. severe infection, haematologic disease, malignity, severe renal or hepatic disease, major depression) in the last 3 months * Patients under experimental pharmaceutical medication

Design outcomes

Primary

MeasureTime frameDescription
Effectiveness of a novel educational program on the quality of life and the clinical outcome.At 12 weeks, after 6 and 9 monthsTherefore quality of life questionnaires are completed at the beginning of the program, at the end of the program (12 weeks), after 6 months and after 9 months. The quality of life questionnaires are Daily life quality index, Skindex 29, EuroQol -5D, Short Form - 36 , Psoriasis disability index, Quality of Life Index for Atopic Dermatitis. The clinical effectiveness is determined by measuring psoriasis area and severity index (PASI) or scoring atopic dermatitis (SCORAD) at the beginning of the program, at the end of the program (12 weeks), after 6 months and after 9 months.

Secondary

MeasureTime frameDescription
Depression severityAt 12 weeks, 6 months and 9 monthsBeck Depression Inventory (BDI) is a self-completed questionnaire with 21 questions. It is one of the most widely used instruments for measuring depression severity. BDI scores are collected during the four study visits.
LifestyleAt 12 weeks, 6 months and 9 monthsPatients are queried for changes in smoking behaviour and physical activity monthly. Also, stress is examined during the four study visits,therefore we use the Everyday Problem Checklist.
Medical consumption and cost-effectiveness evaluationAt 12 weeks, 6 months and 9 monthsMedical therapy of patients is divided into: topical therapy, systemic therapy, combination of topical and systemic therapy or no therapy. Patients are asked for changes in medical therapy monthly. Also, medical consumption is followed: costs for medication and doctor visits related to the management of the skin disease. EuroQol-5D (EQ-5D) questionnaires are used as standardised instrument to measure health outcomes. For cost-utility analysis, gain in quality-adjusted life years utilities is plotted against time, using the area under the curve approach (cost in EUR/EQ-5D gain).

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026